Biosyn is developing a number of microbicides for the prevention of HIV and other sexually transmitted diseases (STDs) including chlamydia, genital herpes and papilloma virus. Each of these compounds is in a different stage of development, with the company's leading microbicide candidate, Savvy (1.0% C31G vaginal gel) entering Phase III clinical trials early in 2003 for contraception, HIV prevention, and prevention of other STDs. Biosyn's receipt of the $10 million grant from the NIH not only ensures the swift progression of CV-N into clinical trials, it is also validation of the company's strategy to develop multiple microbicide candidates in parallel, with the goal of bringing to market one or more microbicides as expeditiously as possible over the next several years. With over 5.3 million people having acquired HIV in the year 2001 alone, there is an urgent need for a microbicide to curb the onslaught of this pandemic as well as provide women with a means of protecting themselves from STDs.
| Website | http://www.biosyn-inc.com |
| Revenue | $20.2 million |
| Employees | View employees |
| Address | 1800 Byberry Rd, Huntingdon Valley, Pennsylvania 19006, US |
| Phone | +1 215-914-0900 |
| Industry | Manufacturing General, Manufacturing |
| Competitors | Thermo Fisher Scientific, Merck Group, Agilent Technologies, Illumina, Beckman Coulter Life Sciences, Bio-Rad Laboratories, QIAGEN, Promega Corporation, Eppendorf Group, SAB Biotherapeutics , Inc. +43 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 2834 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Biosyn , Inc. employee's phone or email?
Biosyn , Inc. Questions
The Biosyn , Inc. annual revenue was $20.2 million in 2026.
Biosyn , Inc. is based in Huntingdon Valley, Pennsylvania.
The NAICS codes for Biosyn , Inc. are [32, 32541, 3254, 325].
The SIC codes for Biosyn , Inc. are [28, 283, 2834].
